Continuing Education Activity

Methamphetamine, a powerful central nervous system stimulant and N-methylated derivative of amphetamine, remains one of the most addictive and dangerous substances encountered in both clinical and community settings. While its pharmaceutical form has limited use in treating attention-deficit/hyperactivity disorder, the drug’s high abuse potential, severe health risks, and unpredictable behavioral effects make it a critical topic for all healthcare professionals.

This activity explores methamphetamine’s pharmacology, approved and illicit uses, mechanisms of action, and toxic effects across multiple organ systems. This activity also addresses current best practices for patient monitoring, early detection of substance misuse, and the safe, evidence-based management of overdose and withdrawal to optimize clinical outcomes and patient safety. This activity provides clinicians with the knowledge and skills to optimize the therapeutic use of methamphetamine, recognize and manage misuse, and respond effectively to associated complications. This promotes the implementation of safe, individualized treatment strategies that balance clinical efficacy with the prevention of abuse and adverse outcomes. In addition, this activity fosters interprofessional collaboration among healthcare providers to enhance communication, coordination, and shared clinical judgment, enabling healthcare teams to prevent harm, support recovery, and optimize patient outcomes.

Objectives:

• Identify the pharmacological properties, mechanisms of action, and clinical indications of methamphetamine.
• Implement evidence-based strategies for managing overdose, withdrawal, and long-term complications.
• Select appropriate interventions to minimize misuse and optimize therapeutic efficacy.
• Collaborate with interprofessional healthcare teams to coordinate comprehensive care for individuals who might benefit from methamphetamine therapy while reducing the risk of misuse.

Indications

Methamphetamine is a potent central nervous system (CNS) stimulant and an N-methylated derivative of amphetamine. The drug exists as 2 stereoisomers:

• d-Methamphetamine (dextromethamphetamine), which is the pharmacologically active isomer in the United States.
• l-Methamphetamine (levomethamphetamine), which is a weaker CNS stimulant that is sometimes present in over-the-counter nasal decongestants.

Methamphetamine is widely recognized as a recreational drug due to its intense euphoric and highly addictive properties. However, in its pharmaceutical formulation, it remains an alternative prescription option for limited and strictly regulated clinical uses.

FDA-Approved Indications

Attention-deficit/hyperactivity disorder: Methamphetamine hydrochloride is approved by the US Food and Drug Administration (FDA) for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 and older as part of a comprehensive treatment program and for short-term use. Clinical practice guidelines, including those issued by the American Academy of Pediatrics, do not recommend methamphetamine as a first-line therapy for ADHD. Instead, safer and more extensively studied agents such as methylphenidate, atomoxetine, guanfacine XR, and clonidine XR are preferred.[1]

Off-Label Use

Methamphetamine has no recognized off-label uses, as its high potential for abuse and significant safety risks severely restrict its clinical application.

Discovery and Abuse Potential

Japanese chemist Nagayoshi Nagai first synthesized methamphetamine from ephedrine in 1893, and Akira Ogata crystallized methamphetamine hydrochloride in 1919, producing a more stable, readily administered form of the drug. In the 1930s, amphetamine entered US clinical use as the Benzedrine inhaler for nasal congestion, while methamphetamine was subsequently marketed under names such as Methedrine for narcolepsy, obesity, and ADHD. Today, only the d-isomer, in the form of Desoxyn, remains FDA-approved; however, its clinical use is limited due to concerns about its potential for abuse liability. Methamphetamine is classified as a Schedule II controlled substance by the United States Drug Enforcement Administration (DEA).[2]

Illicit synthesis of methamphetamine is feasible with relatively simple chemistry, allowing production in small secret laboratories and larger industrial-scale operations in multiple regions. Illicit supply and trafficking remain major drivers of nonmedical use and public-health harm.[3] The use of methamphetamine triggers elevated mood, alertness, increased concentration, energy, decreased appetite, and causes weight loss and increased sexual libido (recreational methamphetamine).

The use of methamphetamine in higher doses can induce psychosis, intracranial bleeding, rhabdomyolysis, and seizures. Moreover, it can cause aggressive behavior, mood swings, paranoia, delirium, auditory and visual hallucinations, and delusions when used chronically. Chronic (long-term) use of methamphetamine can be highly addictive, and abrupt discontinuation of the drug might lead to withdrawal symptoms that can persist for months even after use. The primary obstacles to obtaining methamphetamine treatment include social stigma, the belief that treatment is unnecessary, a preference for withdrawal without assistance, and privacy concerns.[4]

Street Terms for Methamphetamine

Common street terms for methamphetamine include meth, crystal meth, crystal, speed, scootie, yellow powder, crank, ice, spoosh, glass, chalk, redneck cocaine, yellow barn, tina, and tick-tick.[5]

Street Terms for  Smokable  Methamphetamine

Common street names for methamphetamine include hot ice, LA glass, hiropon, super Ice, LA ice, batu, quartz, and hanyak.[6] Awareness of these local terms can help improve detection and communication during clinical screening.

Mechanism of Action

Methamphetamine affects the CNS by enhancing the release of monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine.[7] The use of methamphetamine can lead to many pharmacological effects because of its ability to use various molecular processes.

Methamphetamine increases monoamine levels by:

• Discharging the monoamines from their storage and freeing them into the synaptic space by reversing the action of the dopamine transporters (DATs).
• Obstructing the reuptake of monoamines by blocking the function of monoamine transporters.[8] 
• Increasing the expression of CRE-Luc through activation of trace amine–associated receptors (TAARs) in transfected cells; interacting with TAAR1 to inhibit dopamine uptake in a TAAR1-dependent manner; and exerting a similar effect on brain striatal synaptosomes.[9][10] 
• Reducing the expression of DATs at the cell surface and increasing cytosolic monoamine levels by inhibiting monoamine oxidase (MAO) activity.
• Enhancing the expression and activity of the dopamine-synthesizing enzyme tyrosine hydroxylase.[11]

Attention-Deficit/Hyperactivity Disorder Mechanism

Methamphetamine readily crosses the blood–brain barrier and increases extracellular dopamine and norepinephrine. It achieves this by displacing monoamines from vesicles through vesicular monoamine transporter 2 (VMAT2) and by promoting reverse transport via DAT and norepinephrine transporter (NET).[12][13] The resultant increase in catecholaminergic signaling within prefrontal circuits enhances attention, working memory, and impulse control.

Pharmacokinetics

Absorption: Methamphetamine is absorbed from the gastrointestinal tract.

Distribution: Methamphetamine is highly lipid-soluble, allowing rapid passage across the blood-brain barrier and producing an immediate effect on the CNS.[2]

Metabolism: Methamphetamine is primarily metabolized in the liver through reactions such as aromatic hydroxylation, dealkylation, and deamination. CYP2D6 metabolizes methamphetamine through 4-hydroxylation to pholedrine, and it also functions as a competitive inhibitor of this enzyme. Genetic variability results in 4 phenotypes: poor, intermediate, extensive, and ultrarapid metabolizers, with approximately 5% to 10% of Caucasians being poor metabolizers. Genotype-dependent exposure is clinically significant, as poor metabolizers exhibit higher plasma methamphetamine concentrations and an increased risk of cardiovascular and neurotoxic adverse effects.[14]

Excretion: Methamphetamine is excreted primarily in the urine, and the rate of excretion depends on urinary pH.[15] Alkaline urine markedly prolongs the drug's half-life. Approximately 62% of an oral dose is eliminated in the urine within the first 24 hours, with about one-third excreted as unchanged drug and the remainder as metabolites.

Administration

Available Dosage Forms and Strengths

Pharmaceutical methamphetamine is available as a 5-mg tablet formulation. Illicit formulations may be ingested orally, injected intravenously (IV), smoked, or snorted.

Dosage

• Methamphetamine is approved for the treatment of ADHD in children aged 6 or older. Initial dosage for ADHD is 5 mg once or twice daily, which may be increased in 5 mg increments at weekly intervals. The usual effective dosage is 20 to 25 milligrams per day, administered in divided doses. The maximum recommended dosage is 25 milligrams per day.
• Methamphetamine should not be administered in the late evening to avoid the risk of insomnia.

Specific Patient Populations

Hepatic impairment: No specific dosage adjustment guidance is provided. Because methamphetamine undergoes partial hepatic metabolism via CYP2D6, caution is advised. Initiate treatment at lower doses and titrate carefully.[14]

Renal impairment: Methamphetamine and its metabolites are renally excreted. Although no formal dose adjustment recommendations exist, accumulation may occur in patients with moderate-to-severe renal impairment. Consider dose reduction and closely monitor for signs of toxicity.

Pregnancy considerations:  Animal studies suggest potential fetal harm, and human data show increased risks of premature delivery, low birth weight, and withdrawal symptoms in neonates.[16] Use during pregnancy is not recommended unless the benefits outweigh the risks. Meta-analyses have reported associations between prenatal exposure and impairments in intellectual functioning, problem-solving skills, short-term memory, and language development.[17]

Breastfeeding considerations: Methamphetamine is excreted into breast milk. Both methamphetamine and its metabolite, amphetamine, can be detected in breast milk and infant serum following misuse of methamphetamine by nursing mothers. Serious adverse effects such as irritability, poor feeding, and agitation have been reported in nursing infants. Breastfeeding should be avoided during therapy. Alternative medication is preferred during breastfeeding.[18]

Pediatric patients: Methamphetamine is approved for ADHD in children aged 6 or older. Safety and efficacy are not established in children aged 6 or younger. Chronic use may lead to growth suppression; therefore, height and weight should be monitored regularly.

Older patients: Caution is advised due to an increased risk of cardiovascular disease, hypertension, and CNS adverse effects. Initiate therapy at the lower end of the dosing range.

Adverse Effects

Individuals who use methamphetamine experience a rapid and intense onset of effects typically lasting 5 to 30 minutes, depending on the method of administration. Methamphetamine increases energy levels, suppresses appetite, and produces euphoria for a duration of 6 to 12 hours.[19]

Adverse Drug Reactions

• Decreased appetite
• Nausea
• Psychosis
• Tachycardia
• Hypertension
• Hyperthermia [20]  
• Panic attack
• Mydriasis
• Prickling
• Tingling of fingers and toes
• Disturbed sleep patterns
• Violent, bizarre, and erratic behavior
• Hallucinations and irritability
• Chronic muscle twitches or movements
• Increased intraocular pressure
• Angle closure glaucoma [21]
• Seizures, convulsions, and death from high doses [22]
• Intestinal/mesentric ischemia [23][24][25]
• Hepatic and pancreatic ischemia [26]
• Testicular ischemia [27]

Long-Term Adverse Effects

• Cardiovascular and cerebral blood vessels damage [28]
• Acute coronary syndrome (ACS) and stroke due to hypertension
• Severe tooth degeneration
• Nasal tissue destruction (sniffing)
• Respiratory issues (smoking)
• Infectious diseases/cellulitis/abscesses (injection)
• Weight loss and malnutrition
• Disorientation, apathy, confusion, and exhaustion
• Severe psychological dependence
• Psychosis
• Damage to the brain structure similar to Alzheimer disease, epilepsy, and stroke
• Embolic stroke [29]
• Depression [30]
• Pulmonary hypertension [31][32][33]

Tweaking

The final stage of methamphetamine misuse occurs when the person who inappropriately uses methamphetamine becomes paranoid and irritable, often due to prolonged sleep deprivation lasting approximately 3 to 15 days. This condition is referred to as "tweaking," and the individual exhibiting such behavior is known as a "tweaker." During this stage, tweakers continue to require more methamphetamine to get to the original high.[34] However, achieving this effect becomes increasingly difficult, leading to frustration, irritability, and unstable behavior in the tweaker. Because tweakers are unpredictable, they may display violent tendencies, engage in domestic conflicts, commit impulsive acts, or pose a danger to themselves and others.[35]

A tweaker may appear outwardly normal, with clear eyes, coherent speech, and brisk movements. On closer observation, however, their eye movements may be markedly rapid—up to 10 times faster than usual. Their voice may quiver slightly, accompanied by jerky or restless gestures.

Some tweakers attempt to mask these physical symptoms by using depressants such as alcohol or opioids. However, concurrent depressant use can intensify negative emotions, including paranoia, irritability, and frustration. Other people around these users should exercise extreme caution due to their unpredictable behavior.[36]

Drug-Drug Interactions 

• Monoamine oxidase inhibitors: Co-administration of methamphetamine with MAO inhibitors (MAOIs) is absolutely contraindicated. By blocking the breakdown of monoamines, MAOIs amplify methamphetamine's release of norepinephrine and dopamine, leading to severe hypertensive crisis, hyperthermia, and potentially fatal neurologic complications. A 2-week washout is required before initiating methamphetamine in patients with prior MAOI use.

• Serotonergic drugs: Methamphetamine, when combined with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, triptans, or certain opioids, may increase the risk of serotonin syndrome. Prompt recognition is critical; immediate discontinuation of serotonergic agents and urgent medical intervention are required to prevent progression to life-threatening toxicity.

• Alkalinizing or acidifying agents: Both systemic and urinary pH significantly influence methamphetamine pharmacokinetics. Alkalinization slows renal clearance, thereby intensifying and prolonging drug exposure, whereas acidifying agents accelerate elimination and may reduce efficacy.

• Sympathomimetic drugs: Concurrent use of adrenergic stimulants with methamphetamine produces synergistic effects, substantially increasing the risk of tachyarrhythmias, hypertensive crisis, and CNS overstimulation. If concomitant therapy is unavoidable, employ conservative dosing and ensure continuous cardiovascular monitoring.

• CYP2D6 inhibitors: Inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, can raise systemic methamphetamine levels by impairing metabolism. This enhances both therapeutic and toxic effects, increasing the risk of cardiovascular and neuropsychiatric adverse events.[14]

Contraindications

Absolute Contraindications

• According to product labeling, the absolute contraindication to methamphetamine is in patients with known hypersensitivity to amphetamine or to any component of the methamphetamine formulation. Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported in patients treated with other amphetamine-containing products.
• Methamphetamine is also contraindicated in patients receiving MAOIs or within 14 days of MAOI discontinuation due to the risk of a hypertensive crisis.
• Methamphetamine has been identified as a strong independent predictor of suicidality.[37][38]

Relative Contraindications

• Tourette syndrome
• Hyperthyroidism
• Bipolar disorder
• Psychotic disorder
• History of drug abuse
• Hypertension
• History of myocardial infarction [39][28]
• Coronary artery disease
• Cardiomyopathy [40][41]
• Arrhythmia
• Stroke
• Atherosclerosis
• Seizures [42]
• Breastfeeding mothers
• Increased cardiovascular event risk
• Structural disorder of the heart
• Chronic kidney disease (stage 4 or stage 5) [43]
• Heart failure [44][45][46]

Box Warnings: Addiction, Abuse, and Misuse

• Methamphetamine carries a high potential for abuse and misuse, which can lead to the development of a substance use disorder. Misuse or abuse of CNS stimulants, including methamphetamine, can lead to overdose and death.
• Before prescribing methamphetamine, evaluate the risk of addiction, abuse, and misuse.
• Instruct patients and their families about these risks, the proper storage of each medication, and the safe disposal of any unused drugs.[47]
• Throughout the course of treatment, continually evaluate each patient’s risk and observe for any indications of substance use disorder and addiction.

Monitoring

Methamphetamine users often exhibit distinctive symptoms such as insomnia, acute anxiety, agitation, and psychotic or violent behavior. The onset of such behaviors following methamphetamine use may indicate the development of dependency. Chronic users frequently demonstrate poor personal hygiene and may have skin sores resulting from scratching or picking at imaginary “crank bugs.” Other common signs include an unhealthy complexion, pallor, and tactile hallucinations that often occur in tweakers. Methamphetamine users may develop cracked teeth because of extreme clenching of their jaw when they are high on methamphetamine.

Due to the illicit production, trafficking, and recreational use of racemic methamphetamine, levomethamphetamine, and dextromethamphetamine, this agent is classified as a Schedule II controlled substance under the United States DEA and is regulated internationally under the United Nations Convention on Psychotropic Substances.[2]

Before initiating methamphetamine, evaluate the patient for any underlying cardiac disease. CNS stimulants such as methamphetamine have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Therefore, monitor the patient for motor/verbal tics, as well as worsening of Tourette’s syndrome.[48]

Additionally, monitor baseline and periodic blood pressure and heart rate, as well as ECG, if risk factors are present. Growth monitoring is necessary in pediatric patients. Periodically monitor for substance use disorder. It is essential to monitor for psychiatric status and suicidal tendency or ideations.[37] Check the Prescription Drug Monitoring Program for substance use disorder.[49]

Toxicity

Methamphetamine use can lead to both physical and psychological dependence, accompanied by the development of tolerance. Because of the rapid development of tolerance, methamphetamine users frequently need to increase the dose to get to the satisfying "high," which can be very dangerous because the administration of too much methamphetamine also increases the risk of an overdose.[50] 

Based on the reports from 2011, more than 102,000 emergency department visits in the United States were associated with methamphetamine use. Over half of these cases involved concurrent use of other substances, such as alcohol and marijuana, which can produce synergistic effects. Recognizing the physical and behavioral symptoms of methamphetamine overdose and promptly diagnosing toxicity are essential for saving the patient's life.[51]

Acute Toxicity of Methamphetamine

Acute toxicity results when patients use a large amount of methamphetamine at once, causing an adverse reaction, which may be fatal.

Chronic Toxicity of Methamphetamine

Chronic toxicity occurs as a result of multiple adverse health effects caused by long-term methamphetamine abuse.

Signs and Symptoms of Overdose

• Altered mental status [52]
• Gastrointestinal distress
• Mydriasis
• Bradycardia or tachycardia
• Chest pain
• Shortness of breath [53]
• Arrhythmias [54]
• Hyperthermia [55]
• Myocardial infarction [56]
• Hypertensive emergency [57]
• Acute kidney injury [58][59] 
• Agitation, violent, and psychotic behaviors [60][61]

Patients with acute methamphetamine toxicity often present with altered mental status, which may manifest as irritability, suicidal ideation, and, rarely, coma or seizures. Some patients may exhibit psychotic features, including severe paranoia and tactile hallucinations.

Chronic (long-term) methamphetamine misuse can also cause dental complications, significant weight loss, and dermatological problems such as abscesses.[3][62][63] When methamphetamine is used in combination with opioids or other substances, the overlapping effects may mask the typical clinical features of each drug. Consultation with a medical toxicologist is recommended for appropriate management.[64]

Management of Overdose/Toxicity

The following are the key recommendations, as outlined by the American Society of Addiction Medicine.

• Patients with severe agitation, persistent hypertension, hyperthermia, seizures, chest pain, end-organ dysfunction, or rhabdomyolysis should be admitted.

• Treat seizures with benzodiazepines. Persistent seizures may require second-line agents such as phenobarbital or propofol, with correction of reversible factors such as hyponatremia or hypoxia.

• Agitation and hyperadrenergic symptoms should be managed with benzodiazepines as first-line therapy, titrated to effect and repeated as necessary. If symptoms persist despite adequate GABAergic therapy, adjunctive treatment options include alpha-2 agonists—dexmedetomidine for severe cases or clonidine for milder cases—or beta-blockers with combined alpha-1 antagonistic activity, such as labetalol or carvedilol.[65] Calcium channel blockers or vasodilators are alternatives when beta blockers are contraindicated.

• Stimulant-induced psychosis should be treated with antipsychotics, selected and dosed according to severity. Chlorpromazine and clozapine should be avoided because of increased seizure risk.

• Hyperthermia and neuromuscular overactivity should be managed with aggressive external cooling, IV fluids, and sedation. For core temperatures exceeding 40.5 °C (105 °F), rapid cooling is recommended. Severe cases may require neuromuscular blockade to halt muscle activity.

• Rhabdomyolysis should be treated with aggressive IV hydration to maintain a urine output of more than 2 mL/kg/h. Creatine phosphokinase and renal function should be monitored closely. Urinary alkalinization is not recommended because it may reduce amphetamine elimination.

• Electrolyte abnormalities should be corrected according to standard protocols.

• Hypertensive emergencies should be managed with short-acting vasodilators or alpha antagonists such as sodium nitroprusside, phentolamine, or dihydropyridine calcium channel blockers. Long-acting antihypertensives should be avoided in the acute setting. Nitroglycerin may be administered if myocardial ischemia is present.

• Patients presenting with chest pain or suspected ACS should receive benzodiazepines for the underlying intoxication while undergoing ACS evaluation. Calcium channel blockers or vasodilators are preferred for the management of ischemia. Serial electrocardiograms and troponin measurements should be obtained, and ACS should be treated according to standard protocols. 

• Psychiatric assessment should be performed during the withdrawal phase to evaluate for suicidality and other psychiatric complications.[37]

Enhancing Healthcare Team Outcomes

Methamphetamine should only be prescribed by appropriately trained physicians in case of treatment failure with first-line therapies. Due to the unpredictable behavior, irritability, and the possibility of psychotic symptoms in methamphetamine users, especially during hospital visits due to overdose or complications, the safety of medical and security staff is paramount.[60]

Precautions should always be taken when interacting with these patients, and they should be accompanied by another healthcare professional or security personnel. The triage nurse should be fully informed of the adverse effects of amphetamine and ensure that the emergency department staff are aware of the patient's condition.

A medical toxicologist should be consulted in complex case scenarios and polysubstance ingestion. Critical care consultation becomes necessary in a severe overdose. A cardiologist should be consulted in cases of ACS. In an attempted suicidal overdose or substance use disorder, a psychiatric consultation should be sought. Addiction medicine physicians should manage the long-term stimulant use disorder.

This team-based interprofessional approach to managing these patients should involve physicians, advanced practice providers, nurses, pharmacists, and addiction medicine specialists. The team should collaborate and communicate across disciplines to ensure that patients receive appropriate care, whether for therapeutic indications such as ADHD or stimulant use disorder.[66][67]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W., SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4) [PMC free article: PMC7067282] [PubMed: 31570648]

2.

Cisneros IE, Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. [PMC free article: PMC4315503] [PubMed: 24950453]

3.

Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009 May;60(2):379-407. [PMC free article: PMC2731235] [PubMed: 19328213]

4.

Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis. Drug Alcohol Depend. 2016 Nov 01;168:263-273. [PubMed: 27736680]

5.

Quaranta A, D'Isidoro O, Piattelli A, Hui WL, Perrotti V. Illegal drugs and periodontal conditions. Periodontol 2000. 2022 Oct;90(1):62-87. [PMC free article: PMC9828249] [PubMed: 36183328]

6.

Radfar SR, Rawson RA. Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addict Health. 2014 Summer-Autumn;6(3-4):146-54. [PMC free article: PMC4354220] [PubMed: 25984282]

7.

Der-Ghazarian TS, Charmchi D, Noudali SN, Scott SN, Holter MC, Newbern JM, Neisewander JL. Neural Circuits Associated with 5-HT_1B Receptor Agonist Inhibition of Methamphetamine Seeking in the Conditioned Place Preference Model. ACS Chem Neurosci. 2019 Jul 17;10(7):3271-3283. [PubMed: 31042352]

8.

Aggarwal S, Mortensen OV. Overview of Monoamine Transporters. Curr Protoc Pharmacol. 2017 Dec 20;79:12.16.1-12.16.17. [PMC free article: PMC5841473] [PubMed: 29261228]

9.

Shi X, Swanson TL, Miner NB, Eshleman AJ, Janowsky A. Activation of Trace Amine-Associated Receptor 1 Stimulates an Antiapoptotic Signal Cascade via Extracellular Signal-Regulated Kinase 1/2. Mol Pharmacol. 2019 Oct;96(4):493-504. [PMC free article: PMC6744391] [PubMed: 31409621]

10.

Miner NB, Phillips TJ, Janowsky A. The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity. J Pharmacol Exp Ther. 2019 Oct;371(1):36-44. [PMC free article: PMC6750185] [PubMed: 31320495]

11.

Huang WS, Chen GJ, Tsai TH, Cheng CY, Shiue CY, Ma KH, Yeh SH. In vivo long-lasting alterations of central serotonin transporter activity and associated dopamine synthesis after acute repeated administration of methamphetamine. EJNMMI Res. 2019 Sep 18;9(1):92. [PMC free article: PMC6751231] [PubMed: 31535286]

12.

Srichawla BS, Telles CC, Schweitzer M, Darwish B. Attention Deficit Hyperactivity Disorder and Substance Use Disorder: A Narrative Review. Cureus. 2022 Apr;14(4):e24068. [PMC free article: PMC9097465] [PubMed: 35573587]

13.

Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018 Apr;87:255-270. [PMC free article: PMC8063758] [PubMed: 29428394]

14.

de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farré M. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet. 2012;3:235. [PMC free article: PMC3495276] [PubMed: 23162568]

15.

Huang W, Czuba LC, Isoherranen N. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine. J Pharmacol Exp Ther. 2020 Jun;373(3):488-501. [PMC free article: PMC7250368] [PubMed: 32198137]

16.

Rastegar-Pouyani N, Fakhari F, Lalani AR, Jafarzadeh E, Zafari R, Rahimi N, Habibian Sezavar A, Ostad SN. Prenatal Exposure to Methamphetamine and Its Association With Birth Outcomes: A Meta-Analysis. Birth Defects Res. 2025 Jul;117(7):e2488. [PubMed: 40626732]

17.

Kunkler C, Lewis AJ, Almeida R. Methamphetamine exposure during pregnancy: A meta-analysis of child developmental outcomes. Neurosci Biobehav Rev. 2022 Jul;138:104714. [PubMed: 35661684]

18.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 15, 2025. Methamphetamine. [PubMed: 30000673]

19.

Molla H, DeBrosse J, Keedy S, Lee R, de Wit H. Effects of methamphetamine on two measures of reward: Euphoria and neural activation to reward cues. Neuropsychopharmacology. 2025 Jul;50(8):1298-1304. [PMC free article: PMC12170867] [PubMed: 40269142]

20.

Marco CA, Gupta K, Lubov J, Jamison A, Murray BP. Hyperthermia associated with methamphetamine and cocaine use. Am J Emerg Med. 2021 Apr;42:20-22. [PubMed: 33429187]

21.

Mahjoob M, Heydarian S. Changes in corneal and anterior chamber indices due to methamphetamine abuse. Clin Exp Optom. 2022 Sep;105(7):721-725. [PubMed: 34592112]

22.

Chomchai C, Chomchai S. Global patterns of methamphetamine use. Curr Opin Psychiatry. 2015 Jul;28(4):269-74. [PubMed: 26001916]

23.

Choi K, Imrie A, Lourie R, Cross T. Intestinal ischemia due to methamphetamine use: A case report. Int J Surg Case Rep. 2019;58:11-13. [PMC free article: PMC6462794] [PubMed: 30986641]

24.

Sherkawi E, Aljaafari SA, AlGhannam ZT, Alsafar FA. Intestinal Ischemia Due to Methamphetamine Abuse in a Confused Elderly Patient: A Case Report. Cureus. 2022 Nov;14(11):e31192. [PMC free article: PMC9728079] [PubMed: 36505134]

25.

Anderson JE, Brown IE, Olson KA, Iverson K, Cocanour CS, Galante JM. Nonocclusive mesenteric ischemia in patients with methamphetamine use. J Trauma Acute Care Surg. 2018 Jun;84(6):885-892. [PubMed: 29462085]

26.

Merchant K, Schammel C, Fulcher J. Acute Methamphetamine-Induced Hepatic and Pancreatic Ischemia. Am J Forensic Med Pathol. 2019 Sep;40(3):285-288. [PubMed: 31033491]

27.

Al-Zubaidi M, Stuart A, Jayaratne T, Marsdin E. Non-surgical management of methamphetamine induced testicular ischemia. Urol Case Rep. 2020 Sep;32:101238. [PMC free article: PMC7217995] [PubMed: 32420042]

28.

Ramli FF, Rejeki PS, Ibrahim N', Abdullayeva G, Halim S. A Mechanistic Review on Toxicity Effects of Methamphetamine. Int J Med Sci. 2025;22(3):482-507. [PMC free article: PMC11783064] [PubMed: 39898237]

29.

Lee SJ, Liu S, Blackwill H, Stradling D, Shafie M, Yu W. Cardiomyopathy in Patients With Acute Ischemic Stroke and Methamphetamine Use: Relevance for Cardioembolic Stroke and Outcome. J Am Heart Assoc. 2024 Apr 02;13(7):e033667. [PMC free article: PMC11179773] [PubMed: 38533970]

30.

Leung J, Mekonen T, Wang X, Arunogiri S, Degenhardt L, McKetin R. Methamphetamine exposure and depression-A systematic review and meta-analysis. Drug Alcohol Rev. 2023 Sep;42(6):1438-1449. [PubMed: 37126460]

31.

Ramirez RL, Perez VJ, Zamanian RT. Methamphetamine and the risk of pulmonary arterial hypertension. Curr Opin Pulm Med. 2018 Sep;24(5):416-424. [PMC free article: PMC6880795] [PubMed: 30036313]

32.

Cheng Y, Tung CK, Chung AKK, Liu WW, Huang D, Chan PH, Lam M, Chan WC, Siu CW, Hai JJ. Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study. BMJ Open. 2019 Aug 01;9(8):e027193. [PMC free article: PMC6688696] [PubMed: 31375608]

33.

Guo WJ, Liu DT, Xiao Y, Man TT, Zhang C, Wang Y, Guo W, Chen Y, Wan J. [Methamphetamine-associated pulmonary arterial hypertension: a case report]. Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):261-266. [PubMed: 40050077]

34.

Hauw F, Meppiel E, Steichen O, Conan PL, Capron J, de Broucker T. Isolated persistent acute global amnesia after acute abuse of 3,4-methylenedioxy-methamphetamine (MDMA). J Neurol Sci. 2018 Mar 15;386:36-38. [PubMed: 29406963]

35.

Hoffman WF, Jacobs MB, Dennis LE, McCready HD, Hickok AW, Smith SB, Kohno M. Psychopathy and Corticostriatal Connectivity: The Link to Criminal Behavior in Methamphetamine Dependence. Front Psychiatry. 2020;11:90. [PMC free article: PMC7059248] [PubMed: 32180738]

36.

Kaushal N, Matsumoto RR. Role of sigma receptors in methamphetamine-induced neurotoxicity. Curr Neuropharmacol. 2011 Mar;9(1):54-7. [PMC free article: PMC3137201] [PubMed: 21886562]

37.

Clinical Guideline Committee (CGC) Members; ASAM Team; AAAP Team; IRETA Team. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. 2024 May-Jun 01J Addict Med. 18(1S Suppl 1):1-56. [PMC free article: PMC11105801] [PubMed: 38669101]

38.

Aljadani AH, Abouzed M, Adam H, Alrasheedy BB, Alarfaj M, Alshammari SR, Almuqahwi MS. Methamphetamine use and suicide risk: a comprehensive case-control study. Front Public Health. 2025;13:1593935. [PMC free article: PMC12328327] [PubMed: 40777657]

39.

Schussler JM, Tomson C, Dresselhouse MP. Extreme Hyperthermia Due to Methamphetamine Toxicity Presenting As ST-Elevation Myocardial Infarction on EKG: A Case Report Written With ChatGPT Assistance. Cureus. 2023 Mar;15(3):e36101. [PMC free article: PMC10097605] [PubMed: 37065364]

40.

Thoi F, Scherer DJ, Kaye DM, Sanders P, Stokes MB. Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges. Heart Lung Circ. 2022 May;31(5):616-622. [PubMed: 35153149]

41.

Yu PC, Hsin HT, Lin WT, Huang YC, Huang SH, Weng TH, Wang BL, Chung CH, Fann LY, Chien WC, Yang SS. Increased risk of cardiomyopathy in individuals with methamphetamine related disorders in Taiwan. Sci Rep. 2025 Apr 03;15(1):11449. [PMC free article: PMC11968872] [PubMed: 40180980]

42.

Hass RM, Stitt D. Neurological Effects of Stimulants and Hallucinogens. Semin Neurol. 2024 Aug;44(4):459-470. [PubMed: 38889896]

43.

Baradhi KM, Pathireddy S, Bose S, Aeddula NR. Methamphetamine (N-methylamphetamine)-induced renal disease: underevaluated cause of end-stage renal disease (ESRD). BMJ Case Rep. 2019 Sep 19;12(9) [PMC free article: PMC6754634] [PubMed: 31537605]

44.

Manja V, Nrusimha A, Gao Y, Sheikh A, McGovern M, Heidenreich PA, Sandhu ATS, Asch S. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2023 Jan 11;109(3):168-177. [PubMed: 36456204]

45.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):e263-e421. [PubMed: 35379503]

46.

Thakkar AB, Durstenfeld MS, Ma Y, Win S, Hsue PY. Methamphetamine-associated heart failure: Clinical characteristics and outcomes in a safety net population. Heart Lung. 2025 Mar-Apr;70:214-222. [PMC free article: PMC11980645] [PubMed: 39733607]

47.

Barut E, Barut K. Pediatric methamphetamine poisoning: Case report of a one-year-old child. Ulus Travma Acil Cerrahi Derg. 2025 Jun;31(6):600-602. [PMC free article: PMC12183485] [PubMed: 40511761]

48.

Billnitzer A, Jankovic J. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 Oct;17(4):1681-1693. [PMC free article: PMC7851278] [PubMed: 32856174]

49.

Daniel J, Owen A. Trends in Substance Use Across the Nation and South Dakota. 2016 SpecS D Med. No:13-16. [PubMed: 28817844]

50.

Nie L, Zhaom Z, Wen X, Luo W, Ju T, Ren A, Wu B, London ED, Li J. Factors affecting the occurrence of psychotic symptoms in chronic methamphetamine users. J Addict Dis. 2018 Jul-Dec;37(3-4):202-210. [PubMed: 31682200]

51.

Weng TI, Chen LY, Chen JY, Chen PS, Hwa HL, Fang CC. Characteristics of analytically confirmed illicit substance-using patients in the Emergency Department. J Formos Med Assoc. 2020 Dec;119(12):1827-1834. [PubMed: 32037264]

52.

Rabbany JM, Fitzgerald K, Bowman J, Dong F, Neeki MM. Methamphetamine-induced encephalopathy in the absence of hyperammonemia. BMC Psychiatry. 2023 Apr 20;23(1):276. [PMC free article: PMC10120267] [PubMed: 37081388]

53.

Edinoff AN, Kaufman SE, Green KM, Provenzano DA, Lawson J, Cornett EM, Murnane KS, Kaye AM, Kaye AD. Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities. Health Psychol Res. 2022;10(3):38161. [PMC free article: PMC9476235] [PubMed: 36118981]

54.

Dominic P, Ahmad J, Awwab H, Bhuiyan MS, Kevil CG, Goeders NE, Murnane KS, Patterson JC, Sandau KE, Gopinathannair R, Olshansky B. Stimulant Drugs of Abuse and Cardiac Arrhythmias. Circ Arrhythm Electrophysiol. 2022 Jan;15(1):e010273. [PMC free article: PMC8766923] [PubMed: 34961335]

55.

Kiyatkin EA, Sharma HS. Acute methamphetamine intoxication: brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int Rev Neurobiol. 2009;88:65-100. [PMC free article: PMC3145326] [PubMed: 19897075]

56.

Callaghan RC, Halliday M, Gatley J, Sykes J, Taylor L, Benny C, Kish SJ. Comparative hazards of acute myocardial infarction among hospitalized patients with methamphetamine- or cocaine-use disorders: A retrospective cohort study. Drug Alcohol Depend. 2018 Jul 01;188:259-265. [PubMed: 29793190]

57.

Schwarzbach V, Lenk K, Laufs U. Methamphetamine-related cardiovascular diseases. ESC Heart Fail. 2020 Apr;7(2):407-414. [PMC free article: PMC7160483] [PubMed: 31950731]

58.

Grace Choung HY, Nast CC, Haas M, Lin M, Yamashita M, Hou J. Spectrum of Kidney Biopsy Findings Associated With Methamphetamine Use. Kidney Int Rep. 2024 Jul;9(7):2180-2188. [PMC free article: PMC11284416] [PubMed: 39081731]

59.

Isoardi KZ, Mudge DW, Harris K, Dimeski G, Buckley NA. Methamphetamine intoxication and acute kidney injury: A prospective observational case series. Nephrology (Carlton). 2020 Oct;25(10):758-764. [PubMed: 32725693]

60.

Cohen-Laroque J, Grangier I, Perez N, Kirschner M, Kaiser S, Sabé M. Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2024 May;267:182-190. [PubMed: 38554698]

61.

Srisurapanont M, Likhitsathian S, Suttajit S, Maneeton N, Maneeton B, Oon-Arom A, Suradom C. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. Drug Alcohol Depend. 2021 Feb 01;219:108467. [PubMed: 33385693]

62.

Mizuno S, Ono S, Takano A, Yasunaga H, Iwase H. Dental characteristics associated with methamphetamine use: analysis using forensic autopsy data. BMC Oral Health. 2022 Apr 26;22(1):141. [PMC free article: PMC9044830] [PubMed: 35473930]

63.

Skrypnyk M, Skrypnyk R, Petrushanko T, Skikevych M, Petrushanko V, Skrypnyk I. Case Report: Unusual oral cavity changes associated with methamphetamine abuse. Front Public Health. 2025;13:1473584. [PMC free article: PMC12000065] [PubMed: 40241952]

64.

Glidden E, Suen K, Mustaquim D, Vivolo-Kantor A, Brent J, Wax P, Aldy K., Toxicology Investigators Consortium (ToxIC) Study Group. Characterization of Nonfatal Opioid, Cocaine, Methamphetamine, and Polydrug Exposure and Clinical Presentations Reported to the Toxicology Investigators Consortium Core Registry, January 2010-December 2021. J Med Toxicol. 2023 Apr;19(2):180-189. [PMC free article: PMC10050626] [PubMed: 36650409]

65.

Bjarvin A, Cross S, Holtzman S, Kim J, Bhandohal J, Mann B, GhandForoush A, Joolhar F. Outcomes of beta-blocker therapy in methamphetamine users with cardiovascular conditions. J Investig Med. 2025 Jun;73(5):376-383. [PubMed: 40040260]

66.

Dunn J, Yuan M, Ramírez F, Chokron Garneau H, Brown-Johnson C, Breland H, Antonini V, Larkins S, Rawson R, McGovern M. Addressing Methamphetamine Use in Primary Care: Provider Perspectives. 2023 Jan-Feb 01J Addict Med. 17(1):60-66. [PMC free article: PMC9897271] [PubMed: 35841323]

67.

Pohl L, El-Kurdi R, Selinger R, Sauls A, Rhodes LA, Marciniak MW. Implementation of a community-based pharmacist-run attention deficit hyperactivity disorder clinic in a college health center. J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4S):S178-S183. [PubMed: 33676837]

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.